Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Neuren Pharmaceuticals.
RELATED STOCKHEAD STORIES
News
ScoPo’s Powerplays: ASX health stocks rise as ‘Pro Medicus again hit the ball out of the park’
Health & Biotech
ASX Health Stocks: Neuren’s Angelman drug shows good results, but share price drops 7pc
Health & Biotech
MoneyTalks: Horizon 3 Healthcare is bullish on these two ASX firms
Health & Biotech
ScoPo’s Powerplays: ASX health stocks rise amid renewed positive sentiment
Health & Biotech
ASX Health Stocks: Neuren’s treatment for cruel kids’ disease on fast track
News
Small Caps Lunch Wrap: Markets are down but who cares when these ASX penny stocks have gone quite mad
Health & Biotech
ScoPo’s Powerplays: ASX health stocks end the week ahead despite freaky inflation data
Health & Biotech
ScoPo’s (actually Wilkie’s) Powerplays: ASX health stocks fall but Dimerix and Avita soar
News
Rise and Shine: Everything you need to know before the ASX opens
News
It’s horses for courses and April was ASX Resources: Selfwealth’s latest best of
News
ASX Small Caps Lunch Wrap: Whose flashed boobies have ruined the fun for everyone this week?
News
ASX Small Caps Lunch Wrap: Who’s been busted making cheap Chinese knock-offs this week?
Health & Biotech
ScoPo’s Powerplays: ASX health stocks rise as Polynovo achieves record $10m revenue month
Health & Biotech
Top ASX biotechs catching the eye of analysts and fund managers in 2024 – Part 2
News
ASX Small Caps Lunch Wrap: Who’s worming his way out of being US President this week?
Health & Biotech
ASX Health Stocks: Neuren’s Q1 DAYBUE sales disappoint; 4DX gets another Medicare reimbursement in US
Health & Biotech
